NEW YORK, July 24, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Exelixis, Inc. (NASDAQ: EXEL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=EXEL

Highlights from our EXEL Report include: 


        
        - METEOR, Phase 3 Pivotal Trial Of Cabozantinib -- On July 20, 2015 Exelixis, Inc
          announced positive top-line results from the primary analysis of METEOR, the phase 3
          pivotal trial of Cabozantinib. The Company informed that trial was conducted in
          patients suffering with metastatic renal cell carcinoma (RCC) who have experienced
          disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor
          (TKI). The Company added that the trial compared outcome of administration of
          cabozantinib to everolimus in 658 patients who were enrolled across 200 sites in 26
          countries.



        
        - Trial Met Its Primary Endpoint -- As per the Company, the trial met its primary
          endpoint of demonstrating a statistically significant increase in progression-free
          survival (PFS) in the first 375 randomized patients as determined by an independent
          radiology committee (IRC). Moreover, the trial revealed that Cabozantinib reduced the
          risk of disease progression or death by 42% compared to the everolimus arm (hazard
          ratio [HR]=0.58, 95 percent CI 0.45-0.75, p<0.0001).



        
        - Managements View -- Commenting on the results of METEOR Michael M. Morrissey,
          Ph.D., the Company's President and CEO said, "The positive top-line results from
          METEOR represent strong progress for the kidney cancer community and for Exelixis,
          bringing us one step closer to our shared goal of delivering a new and meaningfully
          differentiated therapeutic option for the many metastatic RCC patients in need. With
          these data now in hand, Exelixis' highest corporate priority becomes the submission of
          U.S. and EU regulatory filings, which we intend to complete in early 2016."



        
        - Other Corporate Updates -- In another release dated July 15, 2015, Exelixis,
          announced that Christopher J. Senner is appointed as its Executive Vice President and
          CFO. Exelixis informed that in his new role Mr. Senner will oversee the Company's
          global finance function, leveraging extensive experience which gained earlier in his
          career. Mr. Senner holds nearly 25 years of experience in biopharmaceutical finance,
          including special expertise in global financial operations and controls, strategic
          planning and analysis, supply chain finance and business development.

To find out how this influences our rating on Exelixis, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=EXEL

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "CFA(R)"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA(R) have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA(R) (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA(R) (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com